Get full access to one story every week, and to summaries of all other stories. Just create a free account

High capital allocations, low public relations. Long gestation businesses, short decision cycles. High absolute returns, low-to-nil asset attachment. This, in a nutshell, is Arun Kumar’s business philosophy. For someone who’s created three public pharma companies, incubated several smaller entities, and seals a new deal sooner than the ink on the previous one has dried, Kumar’s is an unusual wealth generation machine. One that is now being oiled for a different run.

Consider this: Bengaluru-based Strides Pharma Science Ltd grossed Rs 79.9 crore ($11.5 million) in profit (before tax) from continuing operations, but an eye-rolling Rs 625.8 crore ($90 million) profit from discontinued operations in the year ended March 2018. The 29-year-old public company, Kumar’s first, had consolidated revenues of Rs 2,857 crore ($412 million) in the same year.

It’s a similar story at SeQuent Scientific Ltd (SSL), India’s largest animal health company by far; also the second public company from Kumar’s stable. Total profit from discontinued operations in the year ended March 2018 was Rs 420.6 crore ($60.6 million), against a profit of Rs 10 crore ($1.4 million) from continuing operations on consolidated revenues of Rs 866 crore ($125 M).

At Strides alone, if 10 new subsidiaries were created in 2018, nine got divested, as per its annual report. The web of new entities never stops spinning.

“He works in so many areas and with so many companies that, at any point, a subset [of the business] is on a high even if the rest of the industry is on a downturn,” says a company insider who doesn’t want to be named as he isn’t authorised to speak with the media.  

Given all the deals that he has put together over the years, Kumar is arguably “one of the best entrepreneurs India has produced”, says a pharma executive, referring to the frequency of his transactions and distribution of wealth to partners and employees. He doesn’t want to be named because he’s done a several-crore deal with Strides in recent years. After the $1.65-billion sale of its injectables business to global generics giant Mylan Inc. in 2013, Strides returned $525 (pre-tax) million in dividends to shareholders. (Spoiler alert: Promoter groups hold 30.79%, as of March 2018). Additionally, Rs 300-odd crore (~$43 million) was shared with employees.

Kumar declined to be interviewed for this story. “I enjoy being reticent and reclusive. It’s done me good,” he wrote back over email.

In April 2018, Kumar, 58, returned from a one-year retirement-of-sorts to helm Strides again, the only company where he or his family office has a board-level representation. The global pharmaceutical industry headwinds had taken their toll, stocks were down 25%, and the mothership looked shaky.

Towards the end of January 2019, Strides made a string of buying-selling announcements. Curiously, it exited the Australian market, one where it had struck multiple lucrative deals in the past and was among the top three generics suppliers.

AUTHOR

Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 6 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 6 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 6 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at [email protected] with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at [email protected] or follow us on Twitter.